BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34545469)

  • 21. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
    Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
    J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
    Benville JR; Compton P; Giordano NA; Cheatle MD
    Drug Alcohol Depend; 2021 Apr; 221():108619. PubMed ID: 33667781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of PACU length of stay and opioid requirements of patients maintained on buprenorphine or methadone for opioid use disorder.
    Dale RC; Metcalf CL; Bockman C; Langford DJ; Fong CT; Peperzak KA
    J Opioid Manag; 2022; 18(1):7-15. PubMed ID: 35238008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
    Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
    Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterizing acute and postsurgical pain management in patients receiving buprenorphine or buprenorphine/naloxone.
    Jones AC; Tillman F; Kahlon C; Seys R; Pepin M
    J Am Pharm Assoc (2003); 2024; 64(3):102035. PubMed ID: 38364887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
    Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
    Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
    BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder.
    Shulman M; Luo SX; Campbell ANC; Scodes J; Pavlicova M; Broffman A; Saxon AJ; Nunes EV
    J Addict Med; 2020; 14(5):e188-e194. PubMed ID: 32039934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study.
    Hauck TS; Ladha KS; Le Foll B; Wijeysundera DN; Kurdyak P
    Addiction; 2023 Oct; 118(10):1953-1964. PubMed ID: 37332171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.